Based on this, we believe that the experimental results can, to some extent, reflect the in vivo situation in patients with ADTKD‐UMOD, where UMOD mutations may lead to impaired C3b cleavage and complement overactivation. This evidence concerns the gene UMOD and autosomal dominant medullary cystic kidney disease with or without hyperuricemia.